Abstract The adoption of primary (PP) versus secondary prophylaxis (SP) of febrile neutropenia (FN), with granulocyte colony-stimulating factors (G-CSF), for adjuvant chemotherapy (AC) regimens in breast cancer (BC) could be affected by its ''value for money''. This systematic review examined (i) cost-effectiveness of PP versus SP, (ii) FN threshold at which PP is cost-effective including the guidelines 20 % threshold and (iii) potential impact of G-CSF efficacy assumptions on outcomes. The systematic review identified all cost-effectiveness/cost-utility analyses (CEA/CUA) involving PP versus SP G-CSF for AC in BC that met predefined inclusion/exclusion criteria. Five relevant CEA/CUA were identified. These CEA/CUA examined different AC regimens (TAC = 2; FEC-D = 1; TC = 2) and G-CSF formulations (filgrastim ''F'' = 4; pegfilgrastim ''P'' = 4) with varying baseline FN-risk (range 22-32 %), mortality (range 1.4-6.0 %) and utility (range 0.33-0.47). The potential G-CSF benefit, including FN risk reduction with P versus F, varied among models. Overall, relative to SP, PP was not associated with good value for money, as per commonly utilized CE thresholds, at the baseline FN rates examined, including the consensus 20 % FN threshold, in most of these studies. The value for money associated with PP versus SP was primarily dependent on G-CSF benefit assumptions including reduced FN mortality and improved BC survival. PP G-CSF for FN prevention in BC patients undergoing AC may not be a cost-effective strategy at the guidelines 20 % FN threshold.
Introduction
Febrile neutropenia (FN) is associated with significant morbidity, mortality risk and cost [1] [2] [3] [4] . It can also lead to adjuvant chemotherapy treatment delays and/or dose reductions that can potentially affect patient survival [1, 2] . Patients developing FN are often prescribed granulocyte colony-stimulating factors (G-CSF) with subsequent treatment cycles in an attempt to reduce the risk of further FN events (secondary prophylaxis, SP) and maintain chemotherapy relative dose intensity (RDI) [5] [6] [7] . Current practice guidelines recommend G-CSF from the first cycle of chemotherapy (primary prophylaxis, PP) if the predicted FN risk is 20 % or higher [5] [6] [7] .
Globally, adjuvant chemotherapy for breast cancer often consists of taxane-based regimes such as TAC (docetaxel, doxorubicin, cyclophosphamide), FEC-D (Fluorouracil, Epirubicin, Cyclophosphamide, Docetaxel) and TC (Docetaxel, Cyclophosphamide) [8] [9] [10] . PP, as opposed to SP, is currently recommended for most patients treated with these regimens given the C20 % FN risk observed with these regimens outside of clinical trials [11] . PP G-CSF could lead to lower FN management costs and improved patient quality of life due to a reduction in FN event rate, and could also be associated with lower FN mortality and/or improved long-term cancer survival due to improved chemotherapy delivery [12] [13] [14] [15] [16] . PP G-CSF, however, is also associated with significant drug acquisition costs that should be examined within the context of all potential downstream cost savings, quality of life improvements and survival benefits [17] .
The adoption of PP G-CSF for FN prevention in various health care jurisdictions could be affected by its value for money (i.e. cost-effectiveness) [18] [19] [20] . PP versus SP for patients undergoing adjuvant chemotherapy for breast cancer would be associated with significant incremental upfront G-CSF acquisition costs. A critical appraisal of the ''value for money'' of PP G-CSF for febrile neutropenia prevention in breast cancer has not been conducted to date. In the current era of budgetary constraints and value-based frameworks, a systematic review of the ''value for money'' of PP versus SP, in various scenarios including the 20 % FN threshold, could help inform practice guidelines. Cost-effectiveness (CEA) and cost-utility (CUA) analyses examine the incremental costs per life-year (LY) or quality-adjusted life-year (QALY) gained, respectively, associated with an intervention, and can help address the question of ''value in cancer care'' [21] . Interventions associated with incremental costs per QALY gained below commonly utilized cost-effectiveness (CE) thresholds (US$100,000 in the USA, £30,000 in the UK and CAN$100,000 in Canada per QALY gained) provide ''good value for money'' [20, 22] . We conducted a systematic review to examine the ''value for money'' associated with PP versus SP G-CSF for adjuvant chemotherapy in breast cancer.
Methods

Literature search strategy
A literature search involving Pubmed and the Cochrane Database of Systematic Reviews was conducted on 1 December, 2015 to identify all CEA/CUA published up to search date (i.e. December 1, 2015), which examined G-CSF prophylaxis for FN risk reduction during adjuvant chemotherapy in breast cancer. The search included the following keywords: (economic, pharmacoeconomic, price, pricing, cost(s), cost analysis, or cost-effective) and (breast neoplasm(s) or breast cancer) and (granulocyte colony-stimulating factor, G-CSF, filgrastim, or pegfilgrastim). In addition, references from all studies identified by search mentioned above were hand searched to identify potentially overlooked studies (backward search). Further details pertinent to literature search are provided in the online supplementary section (Online Resource 1).
Inclusion and exclusion criteria
Economic evaluations of G-CSF prophylaxis (filgrastim or pegfilgrastim) for FN prevention that met all the following eligibility criteria were included: (i) CEA/CUA studies, (ii) adjuvant chemotherapy for breast cancer, (iii) PP versus SP G-CSF strategies, (iv) outcomes reported in incremental costs per LY or QALY gained. Studies were excluded as follows: (i) review articles and commentaries, (ii) economic evaluations other than CEA/CUA, (iii) publications in a language other than English, (iv) mixed populations involving various cancers if outcomes not reported separately for breast cancer, (v) G-CSF strategies involved different backbone chemotherapy regimens, (vi) G-CSF prophylaxis was intended for bone marrow or peripheralblood stem-cell transplantation and (vii) baseline FN rate examined was not stated/defined.
Data extraction and study aims
The selected studies were reviewed to extract and/or compute all relevant data pertinent to study methods, including key input parameters of G-CSF benefit (i.e. improved quality of life, lower FN-related costs, reduced FN mortality and improved breast cancer survival) and cost-utility outcomes. All relevant data were extracted and/ or computed by two authors (T.Y. and S.J.) with discrepancies resolved by consensus. The aims of this study were (i) to examine the value for money (i.e. cost-effectiveness) of PP versus SP G-CSF for adjuvant chemotherapy in breast cancer, (ii) to identify the FN rate at which PP G-CSF appears to be a cost-effective strategy and its value for money at the consensus guideline 20 % FN threshold and (iii) to evaluate the potential impact of G-CSF efficacy assumptions on outcomes.
Results
Identified studies
The initial search returned 114 publications (Fig. 1 ). Eighty were excluded based on the title and a further 29 after a more detailed review of the abstract/publication. Five studies met the predefined inclusion/exclusion criteria, and were included in this review (Table 1) [23] [24] [25] [26] [27] . Backward search did not identify any other eligible studies. The included studies were conducted in different health care jurisdictions (USA = 1, UK = 1, Canada = 3), involved commonly utilized adjuvant taxane-based regimens (TAC = 2; FEC-D = 1; TC = 2) and all reported on incremental costs per QALY gained albeit at different time horizons (range 3-month to lifetime).
Study methods
All studies incorporated baseline FN risk greater than 20 % (range 22-32 %) and assumed varying impacts of FN on quality of life and/or mortality ( Table 1 ). All evaluations examined PP G-CSF for all chemotherapy cycles, with one [25] also examining PP G-CSF for the D cycles only (FN risk 14.8 %) of FEC-D. All studies incorporated lower FNrelated costs and improved patient quality of life due to reduced FN event rate following G-CSF prophylaxis, but assumed varying survival benefits due to lower short-term FN-related mortality and/or improved long-term breast cancer survival (Table 2) . A public payer perspective was considered by all evaluations, and none accounted for indirect costs or took a societal perspective. Overall, upfront costs of G-CSF drug acquisition and downstream costs of FN management were highest in the USA and lowest in the UK (Table 3) .
Value for money of PP versus SP G-CSF strategies PP G-CSF, with filgrastim (Table 4) or pegfilgrastim ( Table 5 ), was associated with both incremental cost and QALY gains relative to SP in all studies at the baseline FN rate examined in each. Overall, the computed incremental cost per QALY gained was close to or higher than commonly utilized CE thresholds except in the evaluation [25] that examined PP G-CSF only for the D cycles of FEC-D chemotherapy. In all other evaluations [23] [24] [25] [26] [27] , PP G-CSF was associated with a less than 50 % (range 5-42 %) probability of being a cost-effective strategy when judged against commonly utilized CE thresholds in the various jurisdictions studied. In sensitivity analyses, the value for money of PP G-CSF was primarily dependent on FN mortality rate [23, 25, 26] , baseline FN rate [23] [24] [25] [26] , G-CSF costs [23] [24] [25] [26] and impact of PP on FN rate [23, 26] . Conversely, FN utility [23, 26] and chemotherapy characteristics [26] , including price and relative effectiveness, appeared to have relatively little impact on G-CSF value for money. Finally, FN management costs [23, 25, 26] had less significant impact on value for money compared with the above key parameters. Impact of baseline FN rate and the consensus guideline 20 % threshold Unsurprisingly in all evaluations, higher FN rates were associated with improved cost-effectiveness. PP G-CSF was not associated with good value for money at the 20 % FN rate in all studies except the one utilizing PP G-CSF for the D cycles only of FEC-D chemotherapy [25] . PP G-CSF, however, was a cost-effective strategy at higher FN rates. In one Canadian study [26] , PP G-CSF with filgrastim would meet a $100,000/QALY gained threshold at a FN rate [28 % assuming some loss of chemotherapy efficacy at lower chemotherapy doses, and at a [22 % rate assuming further loss of chemotherapy efficacy with every FN event regardless of subsequent chemotherapy doses. In the UK study [24] , PP G-CSF with pegfilgrastim would meet a £30,000/QALY gained threshold at a FN rate greater than 29 %. Finally, in the US study [23] , a FN rate of 40 % but not 20 % was associated with CE less than the $100,000/QALY gained threshold ($49,000 vs. 156,000/ QALY gained, respectively).
Impact of G-CSF benefit assumptions
The cost-effectiveness of PP G-CSF appears to be primarily dependent on assumed survival benefits (i.e. reduced FN deaths and improved breast cancer survival). Indeed, in the one study that assumed no survival benefit [27] , PP versus SP was associated with a very small 0.001 QALY gain and highly unfavourable cost-effectiveness estimates (ICER 2,348,924 per QALY gained) despite an assumed significant 31 % lower absolute FN events (1 vs. 32 %, respectively). In the US and UK evaluations PP primary prophylaxis, SP secondary prophylaxis, G-CSF granulocyte colony-stimulating factor, F Filagrastim, P pegfilgrastim, D docetaxel, D incremental; QALY quality-adjusted life years, ICER incremental cost-effectiveness ratio, CU cost-utility, CE cost-effectiveness, FN febrile neutropenia, NR not reported a CU = £27,027 per QALY gained for ET75 regimen with 31 % baseline FN risk b CE results judged against the commonly utilized higher boundary of favourable CE thresholds (US$100,000 in the USA, £30,000 in the UK and CAN$100,000 in Canada) c Cost-utility $49,000 versus 156,000/QALY gained for FN rates of 40 versus 20 %, respectively [23, 24] , sensitivity analyses that examined the impact of PP G-CSF on breast cancer survival found a positive correlation between survival benefit and value for money. Most importantly perhaps, the impact of the assumed reduction in short-term FN deaths was more pronounced than the impact of any assumed improvements in long-term breast cancer survival. As an example, in one Canadian study [26] , the survival benefits of PP G-CSF were primarily driven by the assumed FN-related mortality avoided (3.5 deaths per 1000 treated) and not the breast cancer relapses prevented due to improved chemotherapy delivery. As well, the more favourable CE results reported in another Canadian study [25] likely partly reflect a higher assumed 6 % FN mortality risk (range 4.5-7.6 %) compared with other studies (range 1.4-3.6 %), resulting in significantly larger numbers of FN deaths avoided (7.3-10.8 and 8.7-12.5 per 1000 treated with filgrastim and pegfilgrastim, respectively) with no assumed improvement in breast cancer survival.
Discussion
The adoption of various medical interventions depends partly on their clinical benefit/risk profile and ''value for money'' among other factors [18, 19] . The value for money of PP G-CSF in the identified studies was judged against commonly employed CE thresholds in the relevant jurisdictions (US$100,000 in the USA, £30,000 in the UK and CAN$100,000 in Canada per QALY gained) but society and payers may adopt higher/different thresholds [18] [19] [20] . For example, the World Health Organization (WHO) defines the ''value for money'' of interventions relative to gross domestic product (GDP) per capita as being (i) highly cost-effective (\GDP/capita), (ii) cost-effective (1-3 times GDP/capita) and (iii) not cost-effective ([3 times GDP/capita) [22] . Value for money should therefore be considered within the context of acceptable and perhaps evolving ''willingness to pay'' (WTP) thresholds in each jurisdiction [28] . The value for money of medical interventions depends on upfront cost and downstream benefits such as cost savings due to the intervention as well as improvement in quality of life and survival. The identified CUAs, from the US, UK and Canada, with varying modelling assumptions and input parameters provide a unique opportunity to examine key drivers of the value for money associated with PP G-CSF across various health care jurisdictions [23] [24] [25] [26] [27] . Overall, and not surprisingly, the CE of PP G-CSF was affected by baseline FN risk and G-CSF acquisition cost. The adoption of PP G-CSF for higher FN risk scenarios as well as successful price negotiations aimed at lowering acquisition cost would improve the value for money further. Perhaps most importantly, and despite the observed heterogeneity in study parameters and assumptions across the identified CUAs, the value for money of PP G-CSF appears primarily dependent on assumptions regarding potential survival benefits achieved with PP G-CSF as opposed to improved quality of life or reduced costs. If the benefits of PP G-CSF were limited to improved FN costs and quality of life, PP G-CSF does not appear to be associated with good value for money.
Our systematic review and derived conclusions have limitations. Firstly, and perhaps most importantly, the CUAs identified have incorporated different key assumptions regarding G-CSF benefits on short-term FN-related mortality and long-term cancer survival among other parameters. Indeed, the potential survival benefit associated with PP G-CSF is not well defined to date, in particular, with regard to long-term breast cancer-specific survival due to improved chemotherapy delivery [14] [15] [16] . Clinical practice guidelines should attempt to provide clear consensus statements regarding the magnitude of survival benefits achieved with PP G-CSF, if any. In the meantime, the heterogeneity across the identified studies provides unique opportunity to examine the robustness of overall findings according to various plausible yet uncertain survival assumptions. Secondly, a number of variables that can affect the ''value for money'' of PP G-CSF were not evaluated, nor consistently examined, across identified studies. As an example, biosimilar G-CSFs could be associated with improved costeffectiveness, relative to currently available filgrastim or pegfilgrastim, assuming lower drug acquisition costs and comparable efficacy. PP G-CSF would also be associated with improved cost-effectiveness in younger versus older patients [23, 24] . Thirdly, indirect costs such as lost productivity and caregiver costs were not considered in any of the CEA/CUAs identified. Value for money would be more favourable if these societal/indirect costs were also incorporated. A direct payer as opposed to a societal perspective, however, is routinely employed by drug funding regulatory agencies, such as the National Institute for Health and Care Excellence (NICE) and the pan-Canadian oncology drug review (pCODR)-expert review committee (pERC) in the UK and Canada, respectively, when addressing the value of cancer care [29, 30] .
PP G-CSF in breast cancer appears to be associated with incremental costs per QALY gained that are higher than commonly utilized CE thresholds, at the baseline FN risks and G-CSF assumptions examined, in almost all evaluations incorporating adjuvant TAC, FEC-D and TC chemotherapy regimens. More importantly, PP G-CSF did not appear to provide good value for money in most evaluations at the 20 % FN threshold currently recommended by practice guidelines [5] [6] [7] despite assuming a FN mortality benefit. PP G-CSF would be associated with improved value for money at higher baseline FN risk and/ or higher WTP thresholds, and if it was also associated with significant improvements in long-term cancer survival due to improved chemotherapy delivery. Further clinical research is required to further elucidate the potential impact of PP G-CSF on short-term FN mortality and long-term cancer survival to more precisely determine its overall value for money.
Key message
Current guidelines recommend primary prophylaxis with granulocyte colony-stimulating factors (G-CSF) for adjuvant chemotherapy regimens associated with a febrile neutropenia risk C20 %. Primary prophylaxis with G-CSF for adjuvant chemotherapy in breast cancer, however, may not be a cost-effective strategy at the current consensus guideline 20 % FN threshold.
